Forbes -- A new anesthesia drug was supposed to be the gem in Schering-Plough’s $14 billion purchase of rival Organon. Schering CEO Fred Hassan told analysts he expected the medicine, used to quickly reverse other drugs that cause paralysis, to “transform anesthesia.” A panel advising U.S. regulators gave the drug, called sugammadex, a unanimous thumbs-up. European regulators approved it.
